Marinus Pharmaceuticals Stock Today
| MRNS Stock | USD 0.33 0.01 3.13% |
Performance0 of 100
| Odds Of DistressOver 80
|
Marinus Pharmaceuticals is selling for under 0.33 as of the 25th of November 2024; that is 3.13 percent increase since the beginning of the trading day. The stock's lowest day price was 0.31. Marinus Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Marinus Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of February 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of July 2014 | Category Healthcare | Classification Health Care |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. The company has 55.19 M outstanding shares of which 5.66 M shares are now shorted by private and institutional investors with about 1.09 trading days to cover. More on Marinus Pharmaceuticals
Moving together with Marinus Stock
Moving against Marinus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Marinus Stock Highlights
| President CEO | Scott MD | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Leverage Shares -3x Short Moderna (MRNA) ETP Securities | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMarinus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Marinus Pharmaceuticals' financial leverage. It provides some insight into what part of Marinus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Marinus Pharmaceuticals (MRNS) is traded on NASDAQ Exchange in USA. It is located in 5 Radnor Corporate Center, Radnor, PA, United States, 19087 and employs 165 people. Marinus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.94 M. Marinus Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 55.19 M outstanding shares of which 5.66 M shares are now shorted by private and institutional investors with about 1.09 trading days to cover.
Marinus Pharmaceuticals currently holds about 168.25 M in cash with (118 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Marinus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationMarinus Pharmaceuticals maintains a total of 55.19 Million outstanding shares. The majority of Marinus Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Marinus Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Marinus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Marinus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Marinus Ownership Details
Marinus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-06-30 | 718.6 K | |
| Ikarian Capital, Llc | 2024-09-30 | 706.2 K | |
| Lion Point Capital, Lp | 2024-09-30 | 693.8 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 582.1 K | |
| Geode Capital Management, Llc | 2024-09-30 | 568.5 K | |
| Renaissance Technologies Corp | 2024-09-30 | 501.9 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 501.8 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 444.2 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 414.3 K | |
| Franklin Resources Inc | 2024-09-30 | 4.7 M | |
| Tang Capital Management Llc | 2024-09-30 | 4.7 M |
Marinus Pharmaceuticals Historical Income Statement
Marinus Stock Against Markets
Marinus Pharmaceuticals Corporate Management
| MBA CMA | CFO Treasurer | Profile | |
| Christina Shafer | Chief Officer | Profile | |
| Joseph MD | Chief Officer | Profile | |
| Thomas Lyons | Chief Officer | Profile | |
| Sasha Ellis | VP Relations | Profile | |
| Lisa Lejuwaan | VP Sales | Profile | |
| Dayong Li | Senior Biometrics | Profile |
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.